Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
Details
More Products & Services
People
Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience
Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery
Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients
Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- New insight into FDA-approved treatment for most common leukemia in the U.S.
- Venetoclax significantly enhances CAR T-cell therapy through immune repair
- Results set the stage for identifying more effective combination therapies
- New insight into FDA-approved treatment for most common leukemia in the U.S.
- Venetoclax significantly enhances CAR T-cell therapy through immune repair
- Results set the stage for identifying more effective combination therapies
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link